CombiMatrix

GenScript believes that CustomArray's oligonucleotide synthesis and microarray manufacturing technology will enable it to better serve its customers.

Invitae issued approximately $21.2 million in shares of its own common stock to former CombiMatrix shareholders. 

The revenue increase was driven by higher test volumes in its reproductive health segment and improved test reimbursement across all segments.

The release of the financial results comes just days after molecular diagnostics firm Invitae announced it will acquire CombiMatrix.

Invitae is interested in companies that can contribute positively to its revenues in the next two to three quarters, according to CEO Sean George. 

The acquisitions will enable Invitae to add reproductive health genetic testing to its portfolio and become what it calls a "comprehensive genomic information company." 

The firm noted that its reproductive health test sales were up 32 percent year over year to $2.9 million, while volume for such tests were up 15 percent.

The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.

The company can now market the test in New York, in addition to other areas of the country where it has already made the assay available.

The firm reported 29 percent growth in its overall testing revenues, driven mainly by higher reproductive test volume and higher per-test revenue.

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.